Regeneron (REGN) Rises 20.2% Since Previous Earnings Report: Will the Momentum Last?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 27 2025
0mins
Should l Buy REGN?
Source: NASDAQ.COM
Earnings Performance: Regeneron reported Q3 2025 adjusted EPS of $11.83, exceeding estimates, but down 5% year-over-year. Total revenues grew 1% to $3.7 billion, driven by Eylea HD and Dupixent sales, despite a significant drop in Eylea sales due to competition.
Collaboration Revenues: Total collaboration revenues increased by 18.6% year-over-year to $2 billion, with Sanofi's collaboration revenues rising 28% to $1.6 billion, primarily from Dupixent sales, while Bayer's revenues decreased by 12%.
Regulatory Updates: The FDA issued a complete response letter for Eylea HD's pre-filled syringe application, while positive opinions were adopted for Dupixent and Libtayo in the EU. Regeneron plans to submit a new application for Eylea HD by January 2026.
Market Outlook: Despite a subpar Growth Score of D, Regeneron has seen upward revisions in estimates, with a Zacks Rank of #3 (Hold), indicating an expected in-line return in the coming months.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise
22 Analyst Rating
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 756.910
Low
637.00
Averages
808.50
High
1057
Current: 756.910
Low
637.00
Averages
808.50
High
1057
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's Dominance in Weight Loss Market
- Market Leadership: Eli Lilly's weight loss drug Zepbound became the best-selling drug globally in 2025, generating $65.2 billion in revenue, a 45% year-over-year increase, demonstrating its strong performance in the rapidly growing weight loss market and solidifying the company's leadership position.
- Emerging Competitors: Regeneron's olatorepatide achieved a 19% mean weight loss in a phase 3 study conducted in China, closely rivaling Zepbound's 20.2%, indicating its potential as a serious competitor in the weight loss drug market that could challenge Eli Lilly.
- New Drug Development Progress: Eli Lilly's oral GLP-1 drug forglipron is expected to launch in the second quarter, and with promising phase 3 results in diabetes and obesity, it could capture a leading share of the oral weight loss market, further enhancing the company's competitive edge.
- Technological Investment and Future Outlook: Eli Lilly is heavily investing in artificial intelligence to accelerate the drug discovery process, a strategy that not only enhances R&D efficiency but could also yield significant financial returns in the future, ensuring its continued dominance in the weight loss market.
See More
Eli Lilly's Leadership in Weight Loss Market
- Market Leadership: Eli Lilly's weight-loss drug Zepbound became the best-selling drug globally in 2025, generating $65.2 billion in revenue, a 45% year-over-year increase, showcasing its strong competitive position in the rapidly growing weight loss market.
- Competitive Threats: Despite Eli Lilly's dominance, competitors like Regeneron, Roche, and Novo Nordisk have shown promising results in China, achieving mean weight losses of 19%, 22.5%, and 19.7% respectively, which could pose future challenges to Zepbound.
- New Product Progress: Eli Lilly's oral GLP-1 drug, forglipron, is expected to launch in Q2, and with strong phase 3 results in diabetes and obesity, it is poised to capture a leading share of the oral weight-loss market, further solidifying its market position.
- Technology Investment: Eli Lilly is heavily investing in artificial intelligence to accelerate drug discovery, a strategy that not only enhances R&D efficiency but could also yield significant financial returns in the future, ensuring its sustained advantage in the weight loss market.
See More
Regeneron's Pipeline Performance Positions Shares for Growth
- Sales Growth: Regeneron's leading drug, Dupixent, generated $17.8 billion in revenue in 2025 and received its ninth approved indication, demonstrating strong market performance that is expected to further drive overall revenue growth for the company.
- Promising New Drug: The GLP-1 diabetes and weight loss drug olatorepatide has shown efficacy similar to leading market drugs in clinical trials, and if approved by the FDA, it could deliver $14.8 billion in annual revenues by 2028, significantly enhancing the company's market position.
- FDA Approval Expectations: The company anticipates at least four FDA approvals in 2023, a positive signal that not only boosts investor confidence but also lays the groundwork for future revenue growth, particularly with the rare disease treatment garetosmab.
- Expansive Market Outlook: Reports indicate that the weight loss drug market is expected to reach $23.6 billion by 2030, and with the potential of its new drugs, Regeneron is well-positioned to capture a significant share of this rapidly growing market, providing substantial returns for investors.
See More
Regeneron: Potential for Doubling Returns Ahead
- Future Earnings Potential: Regeneron Pharmaceuticals has achieved a 106% gain over the past decade and is expected to double returns in the coming years, primarily due to its robust pipeline of 26 late-stage candidates, demonstrating the company's sustained competitiveness in the biotech sector.
- Success of Dupixent: As the company's lead therapy, Dupixent generated $17.8 billion in revenue in 2025 and received FDA approval for allergic fungal rhinosinusitis, marking further expansion in treatment areas and is expected to yield higher profit shares for the company.
- New Drug Development Progress: Regeneron anticipates at least four FDA approvals this year, including garetosmab for a rare genetic disorder, showcasing the company's strong capabilities in innovative drug development, which could further drive future revenue growth.
- Broad Market Prospects: Olatorepatide, as a weight loss and diabetes candidate, is projected to deliver $14.8 billion in annual revenues by 2028, and considering the rapid growth of the weight loss drug market, Regeneron is poised for significant earnings enhancement in the coming years.
See More
Regeneron's Obesity Drug Trial Shows Positive Results
- Clinical Trial Results: Regeneron's obesity treatment olatorepatide showed promising Phase 3 trial results in China, with 604 participants achieving an average weight loss of up to 19% over 48 weeks, indicating significant efficacy and market potential.
- Primary Endpoint Achievement: The trial demonstrated that up to 97% of treated patients lost at least 5% of their body weight, successfully meeting the co-primary endpoints, which underscores olatorepatide's effectiveness in obesity treatment.
- Good Tolerability: Olatorepatide exhibited a favorable tolerability profile, with nausea rates below 10% and vomiting rates below 5%, suggesting an improved daily experience for patients on treatment, which may enhance adherence.
- Broad Market Potential: Under the agreement, Hansoh retains development and commercialization rights in Greater China, while Regeneron holds exclusive rights outside mainland China, Hong Kong, and Macau, highlighting the drug's potential in the global market.
See More
Regeneron and Hansoh Pharma Report Positive Phase 3 Results for Obesity Drug
- Clinical Trial Success: Hansoh Pharma's Phase 3 trial of olatorepatide in China demonstrated significant efficacy, with 604 participants achieving up to 19% mean weight loss and 97% reaching at least 5% weight loss at 48 weeks, indicating the drug's potential in obesity treatment.
- Good Safety Profile: The drug exhibited favorable gastrointestinal tolerability, with nausea rates below 10% and vomiting rates below 5%, along with fewer treatment discontinuations compared to other dual incretin trials, highlighting its relative safety.
- Significant Market Potential: Regeneron holds development and commercial rights for olatorepatide outside mainland China, Hong Kong, and Macau, and the successful trial results could pave the way for its global market introduction, further driving company growth.
- Stock Price Reaction: Despite the positive clinical results, Regeneron's shares fell 2.3% in premarket trading to $742.13, reflecting market caution regarding the drug's launch prospects.
See More
Eli Lilly's Dominance in Weight Loss Market
- Market Leadership: Eli Lilly's weight loss drug Zepbound became the best-selling drug globally in 2025, generating $65.2 billion in revenue, a 45% year-over-year increase, demonstrating its strong performance in the rapidly growing weight loss market and solidifying the company's leadership position.
- Emerging Competitors: Regeneron's olatorepatide achieved a 19% mean weight loss in a phase 3 study conducted in China, closely rivaling Zepbound's 20.2%, indicating its potential as a serious competitor in the weight loss drug market that could challenge Eli Lilly.
- New Drug Development Progress: Eli Lilly's oral GLP-1 drug forglipron is expected to launch in the second quarter, and with promising phase 3 results in diabetes and obesity, it could capture a leading share of the oral weight loss market, further enhancing the company's competitive edge.
- Technological Investment and Future Outlook: Eli Lilly is heavily investing in artificial intelligence to accelerate the drug discovery process, a strategy that not only enhances R&D efficiency but could also yield significant financial returns in the future, ensuring its continued dominance in the weight loss market.
See More
Eli Lilly's Leadership in Weight Loss Market
- Market Leadership: Eli Lilly's weight-loss drug Zepbound became the best-selling drug globally in 2025, generating $65.2 billion in revenue, a 45% year-over-year increase, showcasing its strong competitive position in the rapidly growing weight loss market.
- Competitive Threats: Despite Eli Lilly's dominance, competitors like Regeneron, Roche, and Novo Nordisk have shown promising results in China, achieving mean weight losses of 19%, 22.5%, and 19.7% respectively, which could pose future challenges to Zepbound.
- New Product Progress: Eli Lilly's oral GLP-1 drug, forglipron, is expected to launch in Q2, and with strong phase 3 results in diabetes and obesity, it is poised to capture a leading share of the oral weight-loss market, further solidifying its market position.
- Technology Investment: Eli Lilly is heavily investing in artificial intelligence to accelerate drug discovery, a strategy that not only enhances R&D efficiency but could also yield significant financial returns in the future, ensuring its sustained advantage in the weight loss market.
See More
Regeneron's Pipeline Performance Positions Shares for Growth
- Sales Growth: Regeneron's leading drug, Dupixent, generated $17.8 billion in revenue in 2025 and received its ninth approved indication, demonstrating strong market performance that is expected to further drive overall revenue growth for the company.
- Promising New Drug: The GLP-1 diabetes and weight loss drug olatorepatide has shown efficacy similar to leading market drugs in clinical trials, and if approved by the FDA, it could deliver $14.8 billion in annual revenues by 2028, significantly enhancing the company's market position.
- FDA Approval Expectations: The company anticipates at least four FDA approvals in 2023, a positive signal that not only boosts investor confidence but also lays the groundwork for future revenue growth, particularly with the rare disease treatment garetosmab.
- Expansive Market Outlook: Reports indicate that the weight loss drug market is expected to reach $23.6 billion by 2030, and with the potential of its new drugs, Regeneron is well-positioned to capture a significant share of this rapidly growing market, providing substantial returns for investors.
See More
Regeneron: Potential for Doubling Returns Ahead
- Future Earnings Potential: Regeneron Pharmaceuticals has achieved a 106% gain over the past decade and is expected to double returns in the coming years, primarily due to its robust pipeline of 26 late-stage candidates, demonstrating the company's sustained competitiveness in the biotech sector.
- Success of Dupixent: As the company's lead therapy, Dupixent generated $17.8 billion in revenue in 2025 and received FDA approval for allergic fungal rhinosinusitis, marking further expansion in treatment areas and is expected to yield higher profit shares for the company.
- New Drug Development Progress: Regeneron anticipates at least four FDA approvals this year, including garetosmab for a rare genetic disorder, showcasing the company's strong capabilities in innovative drug development, which could further drive future revenue growth.
- Broad Market Prospects: Olatorepatide, as a weight loss and diabetes candidate, is projected to deliver $14.8 billion in annual revenues by 2028, and considering the rapid growth of the weight loss drug market, Regeneron is poised for significant earnings enhancement in the coming years.
See More
Regeneron's Obesity Drug Trial Shows Positive Results
- Clinical Trial Results: Regeneron's obesity treatment olatorepatide showed promising Phase 3 trial results in China, with 604 participants achieving an average weight loss of up to 19% over 48 weeks, indicating significant efficacy and market potential.
- Primary Endpoint Achievement: The trial demonstrated that up to 97% of treated patients lost at least 5% of their body weight, successfully meeting the co-primary endpoints, which underscores olatorepatide's effectiveness in obesity treatment.
- Good Tolerability: Olatorepatide exhibited a favorable tolerability profile, with nausea rates below 10% and vomiting rates below 5%, suggesting an improved daily experience for patients on treatment, which may enhance adherence.
- Broad Market Potential: Under the agreement, Hansoh retains development and commercialization rights in Greater China, while Regeneron holds exclusive rights outside mainland China, Hong Kong, and Macau, highlighting the drug's potential in the global market.
See More
Regeneron and Hansoh Pharma Report Positive Phase 3 Results for Obesity Drug
- Clinical Trial Success: Hansoh Pharma's Phase 3 trial of olatorepatide in China demonstrated significant efficacy, with 604 participants achieving up to 19% mean weight loss and 97% reaching at least 5% weight loss at 48 weeks, indicating the drug's potential in obesity treatment.
- Good Safety Profile: The drug exhibited favorable gastrointestinal tolerability, with nausea rates below 10% and vomiting rates below 5%, along with fewer treatment discontinuations compared to other dual incretin trials, highlighting its relative safety.
- Significant Market Potential: Regeneron holds development and commercial rights for olatorepatide outside mainland China, Hong Kong, and Macau, and the successful trial results could pave the way for its global market introduction, further driving company growth.
- Stock Price Reaction: Despite the positive clinical results, Regeneron's shares fell 2.3% in premarket trading to $742.13, reflecting market caution regarding the drug's launch prospects.
See More
